Sanofi has agreed to buy US biotech company Translate Bio in a US$3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report.
The French pharmaceuticals firm said it would acquire all outstanding shares of Translate Bio for US$38.00 per share in cash, representing a total equity value of about US$3.2 billion.
The boards of both companies have approved the deal, and the chief executive of Translate Bio and the US company’s largest shareholder have backed it, Sanofi and Translate Bio announced in a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi CEO Paul Hudson said.
In pre-market US trading on Tuesday, August 3, Translate Bio’s stock was up almost 30% in line with the Sanofi offer. In extended trading late on Monday after the Reuters report and before the financial terms had been announced, they had soared more than 70% to above US$50.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI